Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Nepisond** is an Italian specialized very-low-calorie, protein-based enteral nutrition formula used within a short-course protein-sparing modified fast protocol for severe obesity. The formula uses milk whey protein plus free amino acids including arginine, ornithine-alpha-ketoglutarate, taurine, cysteine, tryptophan, hydroxyproline, and citrulline, with linseed oil, L-carnitine, coenzyme Q10, policosanols, fructooligosaccharides, and electrolyte supplementation. It is delivered continuously through a nasogastric tube for approximately 14 days to maintain protein intake while inducing nutritional ketosis and marked caloric restriction. In a 364-patient study, this approach was associated with short-term weight loss and improvements in glycemic, lipid, and blood-pressure measures, although hyperuricemia and transient aminotransferase elevations occurred. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438151/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nepisond.